Last reviewed · How we verify
ADUHELM (ADUCANUMAB-AVWA)
ADUHELM (generic name: ADUCANUMAB-AVWA) is a drug developed by BIOGEN INC. It is currently FDA-approved for Alzheimer's disease.
At a glance
| Generic name | ADUCANUMAB-AVWA |
|---|---|
| Sponsor | BIOGEN INC |
| Target | Amyloid beta A4 protein |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Alzheimer's disease
Common side effects
Key clinical trials
- A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous Dose in Healthy V (Phase 1)
- A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease (Phase 3)
- Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for the Treatment of Patients With With Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) Undergoing Stan (EARLY/Phase 1)
- A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease (Phase 3)
- International Collaboration for Real-World Evidence in Alzheimer's Disease (ICARE AD)- A Prospective Real-World Observational Study of Aducanumab-avwa in Patients With Alzheimer's Disease in the US (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADUHELM CI brief — competitive landscape report
- ADUHELM updates RSS · CI watch RSS
- BIOGEN INC portfolio CI
Frequently asked questions about ADUHELM
What is ADUHELM?
ADUHELM (ADUCANUMAB-AVWA) is a pharmaceutical drug developed by BIOGEN INC, indicated for Alzheimer's disease.
What is ADUHELM used for?
ADUHELM is indicated for Alzheimer's disease.
Who makes ADUHELM?
ADUHELM is developed and marketed by BIOGEN INC (see full BIOGEN INC pipeline at /company/biogen).
What is the generic name of ADUHELM?
ADUCANUMAB-AVWA is the generic (nonproprietary) name of ADUHELM.
What development phase is ADUHELM in?
ADUHELM is FDA-approved (marketed).
What does ADUHELM target?
ADUHELM targets Amyloid beta A4 protein.
Related
- Target: All drugs targeting Amyloid beta A4 protein
- Manufacturer: BIOGEN INC — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Alzheimer's disease